Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvesitetamab plus trifluridine/tipiracil vs placebo plus trifluridine/tipiracil in refractory metastatic colorectal cancer (Phase Ib/III, Ib ongoing)
CTR20254831Phase 3Active
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of suvesitetamab in colorectal cancer (CRC), sponsored by Simcere Pharmaceutical Group. Started Nov 2025; status: active.
02
Drugs
suvesitetamab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20254831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254831.